All About Cataracts

In the past, if you developed cataracts, the only question was when to have cataract surgery.

But today, with recent advances in cataract surgery technology, you can choose among several types of intraocular lenses your cataract surgeon can implant in your eye during the procedure to correct your vision.

In the May 15, 2010 online edition of The Wall Street Journal, Health Journal columnist Melinda Beck outlined the latest intraocular lenses available and the additional cataract surgery cost associated with premium IOLs that reduce your need for bifocals and reading glasses after surgery.

Among the choices noted:

Accommodating IOLs that flex inside the eye in response to focusing effort to restore vision at all distances. Currently, Bausch & Lomb’s Crystalens is the only brand of accommodating IOL that has gained FDA approval for use in the United States. Added cataract surgery cost for a Crystalens IOL: $2,200 to $3,500 per eye.

Multifocal IOLs that have more than one lens power, like bifocal contact lenses. Several brands of multifocal IOLs are available. Added cost for a multifocal IOL: $2,200 to $3,500 per eye.

nanoFLEX IOL. This premium IOL, produced by STAAR Surgical Company (Monrovia, Calif.) is made of a soft biocompatible material called collagen. STAAR’s current nanoFLEX IOL does not yet have FDA approval to be marketed as an accommodating IOL, but cataract surgeons who have used the device say it provides a wider range of vision than conventional IOLs. Currently, the nanoFLEX does not cost significantly more than other monofocal (single-power) IOLs covered by Medicare.

Ms. Beck says that though less than 20 percent of people undergoing cataract surgery today are choosing premium IOLs, that may change as more seniors see the value of paying extra for premium IOLs that reduce their dependence on eyeglasses after surgery.

Bausch & Lomb (Rochester, N.Y.) announced today that it will celebrate the tenth anniversary of its Crystalens accommodating intraocular lens (IOL) this weekend and next week at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) being held in Boston.

Crystalens currently is the only accommodating IOL that has received FDA approval for use in cataract surgery performed in the United States. The lens is designed to restore vision at all distances after cataract removal, including near vision lost to age-related presbyopia.

Broadway, film and television actress Florence Henderson recently had the Crystalens IOL implanted in her eye during cataract surgery and will be at the Bausch & Lomb booth at the ASCRS meeting on Sunday, April 11 at 1 p.m. to discuss her satisfaction with the accommodating IOL.

“I’m very pleased to have experienced such a dramatic improvement in my vision since my Crystalens surgery,” she said in a press release issued today by Bausch & Lomb.

During the Crystalens 10-year anniversary celebration, Bausch & Lomb also will honor 12 cataract surgeons who have implanted more than 1,000 Crystalens accommodating IOLs.

For more information about Crystalens intraocular lenses, visit www.crystalens.com.

Crystalens HD, an accommodating intraocular lens (IOL), is producing excellent visual outcomes and a high degree of independence from eyeglasses after cataract surgery, according to three European eye surgeons.

The surgeons presented their findings at the 2010 winter meeting of the European Society of Cataract and Refractive Surgeons, held in Budapest, Hungary, February 12-14.

Mark Tomalla, MD, of Duisburg, Germany, said he has implanted the Crystalens HD accommodating IOL in a series of 48 patients. At the time of his presentation, 17 of these patients had been been evaluated at a 6-month follow-up visit.

Six months after surgery:

• All patients could see clearly in the distance and at arm’s length without glasses.
• 71 percent reported they did not need reading glasses.
• The remaining 29 percent said they needed reading glasses only occasionally.

Angel Lopez-Castro, MD, reported similar results in his surgical implantation of the Crystalens HD after cataract removal in the eyes of 42 patients in Madrid, Spain. He said 80 percent of these patients achieved uncorrected reading vision of 20/25 or better, and all patients had distance vision of 20/20 or better without glasses.

Kristien Vanhoucke, MD, of Mol, Belgium, reported that 6 months after implanting the Crystalens HD in 26 eyes, 90 percent of these patients reported good vision at all distances and freedom from glasses after cataract surgery.

Crystalens HD is the fourth-generation accommodating IOL produced by Bausch & Lomb (Rochester, NY). The company received approval from the U.S. Food and Drug Administration (FDA) in June 2008 to market Crystalens HD in the United States.

In January 2010, Bausch & Lomb announced the introduction of Crystalens AO, its latest accommodating IOL that is designed to reduce higher-order aberrations for even sharper vision after cataract removal.

All Crystalens accommodating IOLs are premium intraocular lenses and therefore increase cataract surgery cost. Ask your cataract surgeon for details.

SOURCE: Multiple European clinics report promising accommodating IOL visual outcomes. Ocular Surgery News. Published online February 15, 2010.

Bausch & Lomb today announced the worldwide launch of a new accommodating intraocular lens (IOL) with aspheric optics for use in cataract surgery.

The new IOL, called Crystalens AO, is designed to be free of spherical aberration that affects other IOLs and thereby produce sharper vision after cataract surgery. The announcement follows recent FDA approval of the Crystalens AO for use by cataract surgeons in the United States.

The aspheric optical surfaces of Crystalens AO are designed to improve retinal image quality without compromising depth of field, and therefore the new IOL provides higher quality distance and intermediate vision than other IOLs, according to the company.

“The Crystalens AO has zero spherical aberration, and the combination of the Crystalens platform and AO optics work together to enhance depth of field,” says Andy Corley, president of Bausch & Lomb’s global surgical division in a press release issued today by the company.

The Crystalens AO is the latest addition to the Crystalens line of accommodating IOLs produced by Bausch & Lomb, joining the Crystalens HD and the Crystalens Five-O. Currently, Crystalens is the only brand of accommodating IOL that is FDA-approved for use in cataract surgery performed in the United States.

Unlike conventional IOLs, the optical portion of accommodating IOLs can move slightly within the eye in response to focusing effort, to improve not only distance vision, but intermediate and near vision as well, reducing the need for reading glasses after cataract surgery.

Accommodating IOLs are a premium intraocular lens and therefore will increase your cataract surgery cost.

More information about Crystalens accommodating IOLs is available on Bausch & Lomb’s Crystalens website or by calling the company at 1-877-SEE BETTER.